Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.

Gonzalez D, Fearfield L, Nathan P, Tanière P, Wallace A, Brown E, Harwood C, Marsden J, Whittaker S.

Br J Dermatol. 2013 Apr;168(4):700-7. doi: 10.1111/bjd.12248. Review.

PMID:
23360189
2.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
3.

Molecular platforms utilized to detect BRAF V600E mutation in melanoma.

Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG.

Semin Cutan Med Surg. 2012 Dec;31(4):267-73. doi: 10.1016/j.sder.2012.07.007.

PMID:
23174497
4.

Vemurafenib: a guide to its use in unresectable or metastatic melanoma.

Keating GM, Lyseng-Williamson KA.

Am J Clin Dermatol. 2013 Feb;14(1):65-9. doi: 10.1007/s40257-012-0007-3.

PMID:
23329082
5.

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS.

Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Review.

6.

Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.

Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, Hillman G, Wu L, Lawrence HJ.

Diagn Mol Pathol. 2012 Mar;21(1):1-8. doi: 10.1097/PDM.0b013e31823b216f.

PMID:
22306669
7.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
8.

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. No abstract available.

PMID:
24933605
9.

Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.

Busser B, Leccia MT, Gras-Combe G, Bricault I, Templier I, Claeys A, Richard MJ, de Fraipont F, Charles J.

JAMA Dermatol. 2013 Dec;149(12):1403-6. doi: 10.1001/jamadermatol.2013.8198.

PMID:
24108467
10.

Community experience of vemurafenib for BRAF(V600) melanoma.

Hersey P.

Lancet Oncol. 2014 Apr;15(4):369-70. doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27. No abstract available.

PMID:
24582506
11.

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.

Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, Marshall E, Plummer R, Proudlove C.

Pharmacoeconomics. 2013 Dec;31(12):1121-9. doi: 10.1007/s40273-013-0094-x. Review.

PMID:
24114739
12.

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Ravnan MC, Matalka MS.

Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Review.

PMID:
22742884
13.

Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.

Seeley AR, De Los Santos JF, Conry RM.

Melanoma Res. 2015 Jun;25(3):246-51. doi: 10.1097/CMR.0000000000000154.

PMID:
25746037
14.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

Owen JL, Lopez IE, Desai SR.

J Drugs Dermatol. 2015 May;14(5):509-10.

PMID:
25942671
15.

Targeted therapies for cutaneous melanoma.

Kee D, McArthur G.

Hematol Oncol Clin North Am. 2014 Jun;28(3):491-505. doi: 10.1016/j.hoc.2014.02.003. Epub 2014 Apr 3. Review.

PMID:
24880943
16.

Vemurafenib: the first drug approved for BRAF-mutant cancer.

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P.

Nat Rev Drug Discov. 2012 Nov;11(11):873-86. doi: 10.1038/nrd3847. Epub 2012 Oct 12. Review.

PMID:
23060265
17.

Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.

Arance AM, Berrocal A, Lopez-Martin JA, de la Cruz-Merino L, Soriano V, Martín Algarra S, Alonso L, Cerezuela P, La Orden B, Espinosa E.

Clin Transl Oncol. 2016 Nov;18(11):1147-1157. Epub 2016 Mar 17.

PMID:
26983408
18.

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.

Eur J Cancer. 2014 Feb;50(3):611-21. doi: 10.1016/j.ejca.2013.11.002. Epub 2013 Nov 29.

PMID:
24295639
19.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.

Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25037139
20.

Vemurafenib: in unresectable or metastatic melanoma.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000. Review.

PMID:
22946753

Supplemental Content

Support Center